Medical tests

Talis Biomedical Announces First Quarter 2021 Financial Results and Business Progress

Tuesday, May 11, 2021 - 9:05pm

b'MENLO PARK, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today reported financial results and business progress for the first quarter ended March 31, 2021.\n"The COVID-19 pandemic has dramatically increased demand for testing to diagnose infectious diseases in widely distributed locations.

Key Points: 
  • b'MENLO PARK, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today reported financial results and business progress for the first quarter ended March 31, 2021.\n"The COVID-19 pandemic has dramatically increased demand for testing to diagnose infectious diseases in widely distributed locations.
  • We believe that this is part of a broader transformational shift of diagnostic testing towards the point-of-care," said Brian Coe, Chief Executive Officer of Talis.
  • "Our solution to meet this demand is Talis One\xe2\x84\xa2, a diagnostic testing platform enabling us to design and commercialize rapid, high quality multiplex assays to detect a wide-range of pathogens, beginning with COVID-19.
  • Leveraging the recent completion of our successful initial public offering, we are well-positioned financially and operationally to help drive this transformation in how care is delivered.

CDC Announces COVID-19 At-Home, Rapid Testing Approach Pioneered by eMed for International Travel to Enter the United States

Tuesday, May 11, 2021 - 8:46pm

b'MIAMI, May 11, 2021 /PRNewswire/ -- eMed , a telehealth company, announces updated guidelines by the U.S. Centers for Disease Control and Prevention (CDC) for international airline travelers re-entering the United States.

Key Points: 
  • b'MIAMI, May 11, 2021 /PRNewswire/ -- eMed , a telehealth company, announces updated guidelines by the U.S. Centers for Disease Control and Prevention (CDC) for international airline travelers re-entering the United States.
  • Passengers may now use eMed\'s pioneering digital-point-of-care platform, offering third-party guided and verified COVID-19 at-home rapid antigen testing with certified results in minutes and automated reporting.\nThe home test administered by eMed provides greater access to individuals needing a reliable, quick and easy rapid antigen test for COVID-19 detection.
  • "This is an important step in getting validated rapid antigen testing approved for use so international travelers entering the United States may do so with greater ease, in addition to being an important step in our collective efforts to reactivate our economy.
  • 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/cdc-announces-covid-19-at-home-r...\n'

Quest Diagnostics Expands Eligibility for $0 Out-of-Pocket COVID-19 Testing Through QuestDirect™ To Assist in Combatting the Pandemic and Help Support Safer Travel, Events and Gatherings Nationwide

Tuesday, May 11, 2021 - 2:05pm

"As more people are vaccinated and the economy opens, greater flexibility and affordability in COVID-19 testing will help keep us all safer.

Key Points: 
  • "As more people are vaccinated and the economy opens, greater flexibility and affordability in COVID-19 testing will help keep us all safer.
  • We believe this option for COVID-19 testing will enable individuals and families to return to normal activities more safely and responsibly.
  • Our QuestDirect consumer-initiated test platform provides dozens of tests for conditions ranging from heart health to sexually transmitted diseases.
  • We were among the first diagnostic information services providers to offer free access to test results online and other channels.

Accellix Expands its Leadership Team

Tuesday, May 11, 2021 - 1:05pm

He has recently worked as the Engineering Leader at Becton Dickinson and Thermo Fisher Scientific, improving, and scaling up their production processes and equipment.

Key Points: 
  • He has recently worked as the Engineering Leader at Becton Dickinson and Thermo Fisher Scientific, improving, and scaling up their production processes and equipment.
  • I am excited to join Accellix\xe2\x80\x99s strong team in the pursuit of enabling our customers to achieve their goals.\xe2\x80\x9d\nIn addition to the expansion of the leadership team, Accellix added a new role of VP Products.
  • I will operate with the goal of turning the Accellix Platform into the cell therapy gold standard.
  • We are currently developing more than twenty assays that will allow for the migration from traditional flow cytometers to the Accellix Cartridge Based Platform.

Government of Canada increases access to COVID-19 rapid testing for workers

Friday, May 7, 2021 - 4:50pm

Workplace screening is another layer of protection for workers, the people they serve and their communities from COVID-19.

Key Points: 
  • Workplace screening is another layer of protection for workers, the people they serve and their communities from COVID-19.
  • Across the country, these rapid tests have already helped to identify and stop the transmission of over 11,000 confirmed cases of COVID-19.\nThis initiative builds on previous successful rapid testing projects supported by the Government of Canada, including through the Creative Destructions Lab Rapid Screening Consortium .
  • "\n"The Government of Canada is implementing a multi-layered strategy and response to the COVID-19 pandemic through a combination of efforts.
  • "\nRapid antigen testsalso referred to as rapid screens or rapid testsare easy to administer, and produce results in as little as 15 minutes.

Stop the spread! Could diagnostic antigen tests help control COVID-19 transmission in workplaces?

Friday, May 7, 2021 - 4:01pm

The findings are presented in anew joint technical report, which includes a survey of EU-OSHAs focal points on the current use of rapid antigen tests in a workplace context in the EU/EEA.

Key Points: 
  • The findings are presented in anew joint technical report, which includes a survey of EU-OSHAs focal points on the current use of rapid antigen tests in a workplace context in the EU/EEA.
  • It builds on the body of knowledge regarding the use of rapid antigen tests provided in ECDC reports.
  • The report shows that rapid antigen testing can help reduce the spread of the virus in high-risk indoor workplaces.
  • However, the report stresses that testing cannot replace other safety and health measures and should be used to complement them.

Bionano Genomics to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 13, 2021

Thursday, May 6, 2021 - 9:01pm

b'To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.

Key Points: 
  • b'To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.
  • The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools.
  • Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs.
  • Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns.

Therma Bright Enters into Agreement to Distribute a 15 Minute Rapid COVID-19 Antibody Test

Thursday, May 6, 2021 - 12:00pm

The new product will be branded Therma Bright\'s AcuVid\xe2\x84\xa2 COVID-19 Rapid Antibody Test.

Key Points: 
  • The new product will be branded Therma Bright\'s AcuVid\xe2\x84\xa2 COVID-19 Rapid Antibody Test.
  • The antibody test has received CE mark in Europe and ANVISA regulatory clearance in Brazil.
  • This AcuVid\xe2\x84\xa2 Antibody test will be Therma Bright\'s second rapid test for serial screening.\n"We are pleased to secure this new AcuVid\xe2\x84\xa2 COVID-19 Rapid Antibody Test that will complement Therma Bright\'s AcuVid\xe2\x84\xa2 COVID-19 Rapid Antigen Saliva Test, as more people are infected and while the vaccine roll out continues," explained Rob Fia, CEO of Therma Bright.
  • We\'re currently in discussions to supply our new AcuVid\xe2\x84\xa2 COVID-19 Rapid Antibody Test to selected customers in Europe and South America.

Major independent study shows Transpara® AI by ScreenPoint Medical can reduce radiologists' workload up to 70% for both 2D and 3D mammography

Thursday, May 6, 2021 - 9:00am

The authors also found that using Transpara AI to transition from 2D to 3D mammography (digital breast tomosynthesis) screening would yield a 30% reduction in workload, a 25% improvement in sensitivity and a 27% reduction in the screening recall rate.

Key Points: 
  • The authors also found that using Transpara AI to transition from 2D to 3D mammography (digital breast tomosynthesis) screening would yield a 30% reduction in workload, a 25% improvement in sensitivity and a 27% reduction in the screening recall rate.
  • Furthermore, many countries are challenged with the backlog of diagnosed cancer cases due to Covid-19 screening delays.
  • The higher the number the higher the risk, enabling radiologists to focus on those women facing the highest risk.
  • This saving is so important as there is a global shortage of radiologists, with workload also on the increase due to the introduction of new imaging techniques such as 3D breast tomosynthesis."

Quidel Forms Retail Collaboration With Walgreens for Over-the-Counter Sale of QuickVue® At-Home OTC COVID-19 Tests

Thursday, May 6, 2021 - 1:30am

The shelf-stable packages, each containing two of the self-administered rapid antigen tests, can also be ordered online at Walgreens.com for store pick-up or same day delivery.\n\xe2\x80\x9cThis retail collaboration with Walgreens will expedite in-store availability and over-the-counter sales of our QuickVue At-Home OTC COVID-19 antigen tests to consumers nationwide,\xe2\x80\x9d said Douglas Bryant, president and CEO of Quidel Corporation.

Key Points: 
  • The shelf-stable packages, each containing two of the self-administered rapid antigen tests, can also be ordered online at Walgreens.com for store pick-up or same day delivery.\n\xe2\x80\x9cThis retail collaboration with Walgreens will expedite in-store availability and over-the-counter sales of our QuickVue At-Home OTC COVID-19 antigen tests to consumers nationwide,\xe2\x80\x9d said Douglas Bryant, president and CEO of Quidel Corporation.
  • The QuickVue\xc2\xae At-Home OTC COVID-19 Test has not been FDA cleared or approved.
  • For more information about Quidel, visit quidel.com .\nThis press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties.
  • You are cautioned not to place undue reliance on these forward-looking statements, which reflect management\xe2\x80\x99s analysis only as of the date of this press release.